4 November 2019


Highlights of Oncode’s Glioblastoma Workshop

On October 16th 2019, Oncode held the second in the series of clinical workshops with the aim to strengthen the link between fundamental and clinical research.

Vesna de Jong

The goal of the Glioblastoma workshop was to present current trends in clinical research, explore how fundamental research can address unmet clinical needs and stimulate new collaborations (translational and clinical) that could be eligible for Oncode funding.

Glioblastoma is an aggressive disease with a very high unmet clinical need where almost all patients experience recurrence. In the last 40 years, there has been very little progress in the area of recurrent glioblastoma, and within the field of neuro-oncology, a number of failed clinical studies have been performed.

While the Hartwig foundation performs whole genome sequencing on tumor samples, so far only a few samples have a neuro-oncological diagnosis. Access to patient material in general is seen as a challenge for the glioblastoma researchers.

Glioblastoma workshop

During the workshop, a few opportunities have been identified. One of them is to make sure that more glioblastoma patients are included in the Hartwig database and that better use is made of the currently available data. In addition, existing mouse models could be used to first test clinical ideas.

Oncode Investigator Leila Akkari (NKI), who was one of the speakers, said: “This workshop was organized as an informal and open discussion between scientists and clinicians about our scientific goals and shortcomings in glioblastoma research and treatment. With it, the opportunity was created to brainstorm and exchange ideas on alternative and innovative treatment strategies that could tackle the limited options we currently provide to glioblastoma patients with important insights from clinicians, particularly regarding the need to always seek better quality of life for patients. I strongly believe it paved the way for long lasting exchanges between fundamental and applied researchers that could lead to illuminating times ahead for clinical translation.”

Other News

Founding Principles Card@2X
New vacancies at Oncode Partner Institutes
Are you planning on the next steps in your scientific career? Check out the latest vacancies at the labs of Oncode Investigators.
About Card
Researchers explain the added value of Oncode Institute
At this year's Oncode-CGC Annual conference, we took the time to speak with some of our Oncode Investigators. In this video, they explain the value that Oncode adds to their research, collaboration opportinuties and valorization success.
Oncode Institute invests 4 million euros in new technology for cancer research in the Netherlands
Oncode Institute invests 4 million euros in unique, state-of-the-art technology for cancer research. Five projects have been awarded within the Infrastructure & Technologies Programme. These technologies will not only become available for the twelve institutes that are affiliated with Oncode Institute but will also be made available to the wider research community in the Netherlands.